Olanzapine increases hepatic glucose production through the activation of hypothalamic adenosine 5′-monophosphate-activated protein kinase

2013 ◽  
Vol 15 (12) ◽  
pp. 1128-1135 ◽  
Author(s):  
M. Ikegami ◽  
H. Ikeda ◽  
T. Ohashi ◽  
M. Ohsawa ◽  
Y. Ishikawa ◽  
...  
Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 2441-PUB ◽  
Author(s):  
QUAN PAN ◽  
YUNMEI CHEN ◽  
HUI YAN ◽  
WANBAO YANG ◽  
ZHENG SHEN ◽  
...  

2013 ◽  
Vol 702 (1-3) ◽  
pp. 302-308 ◽  
Author(s):  
Ling-Jie Kong ◽  
Wen Feng ◽  
Michael Wright ◽  
Yuli Chen ◽  
Qing Dallas-yang ◽  
...  

Molecules ◽  
2021 ◽  
Vol 26 (5) ◽  
pp. 1239
Author(s):  
Tipthida Pasachan ◽  
Acharaporn Duangjai ◽  
Atcharaporn Ontawong ◽  
Doungporn Amornlerdpison ◽  
Metee Jinakote ◽  
...  

This study investigated the effects of Tiliacora triandra (Colebr.) Diels aqueous extract (TTE) on hepatic glucose production in hepatocellular carcinoma (HepG2) cells and type 2 diabetic (T2DM) conditions. HepG2 cells were pretreated with TTE and its major constituents found in TTE, epicatechin (EC) and quercetin (QC). The hepatic glucose production was determined. The in vitro data were confirmed in T2DM rats, which were supplemented daily with 1000 mg/kg body weight (BW) TTE, 30 mg/kg BW metformin or TTE combined with metformin for 12 weeks. Results demonstrate that TTE induced copper-zinc superoxide dismutase, glutathione peroxidase and catalase genes, similarly to EC and QC. TTE decreased hepatic glucose production by downregulating phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) and increasing protein kinase B and AMP-activated protein kinase phosphorylation in HepG2 cells. These results correlated with the antihyperglycemic, antitriglyceridemic, anti-insulin resistance, and antioxidant activities of TTE in T2DM rats, similar to the metformin and combination treatments. Consistently, impairment of hepatic gluconeogenesis in T2DM rats was restored after single and combined treatments by reducing PEPCK and G6Pase genes. Collectively, TTE could potentially be developed as a nutraceutical product to prevent glucose overproduction in patients with obesity, insulin resistance, and diabetes who are being treated with antidiabetic drugs.


2013 ◽  
Vol 51 (01) ◽  
Author(s):  
S Gul ◽  
KH Holzmann ◽  
F Leithäuser ◽  
H Maier ◽  
B Böhm ◽  
...  

1989 ◽  
Vol 120 (3_Suppl) ◽  
pp. S20
Author(s):  
M.J. MÜLLER ◽  
K.J. ACHESON ◽  
A. G. BURGER ◽  
E. JEQUIER ◽  
A. VON ZUR MÜHLEN

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 64-LB
Author(s):  
JEONGRIM KO ◽  
TAE NYUN KIM ◽  
DAE YUN SEO ◽  
JIN HAN

Sign in / Sign up

Export Citation Format

Share Document